Particle Size News and Research

RSS

Liquidia to explore PRINT particle technology with PATH Malaria Vaccine Initiative

Liquidia Technologies today announced a collaboration with the PATH Malaria Vaccine Initiative (MVI) to explore the use of the company's PRINT® particle technology to design next generation malaria vaccines. PRINT technology offers unprecedented control of particle size, shape and chemistry in a highly consistent and scalable manufacturing process, and will be used to deliver a protein in combination with immune stimulating molecules.

10 Feb 2011

Particle Sciences announces strategic alliance with HORIBA Instruments

Particle Sciences, Inc., a leading pharmaceutical CRO, is pleased to announce the establishment of a strategic alliance with HORIBA Instruments of Irvine, CA, which is the U.S. sales and marketing division of HORIBA Limited of Kyoto, Japan.

8 Feb 2011

iFyber receives U.S. Army research Ffunding for wound healing technology

The United States Army Medical Research and Material Command, through the support of the Department of Defense Small Business Innovation Research Grant Program (SBIR), has awarded iFyber a Phase I grant. The award funds research related to controlled release of nitric oxide for wound healing.

7 Feb 2011

FDA approves ultrasmall silica inorganic nanoparticle INDA for targeted molecular imaging of cancer

Researchers at Memorial Sloan-Kettering Cancer Center's Nanotechnology Center, along with collaborators at Cornell University and Hybrid Silica Technologies, have received approval for their first Investigational New Drug Application from the US Food and Drug Administration for an ultrasmall silica inorganic nanoparticle platform for targeted molecular imaging of cancer, which may be useful for cancer treatment in the future.

31 Jan 2011

IDEX enters definitive merger agreement to acquire Microfluidics International

IDEX Corporation today announced that it has entered into a definitive merger agreement to acquire Microfluidics International Corporation for $1.35 per share, net to the seller in cash, and subject to adjustment as provided in the merger agreement. The transaction is expected to close in the first quarter of 2011.

11 Jan 2011

Smith & Nephew's VERILAST technology shows superior survivorship than other hip replacement implants

A newly released patient registry reports that hip replacement implants made from ceramicized metal heads which articulate against polyethylene lined cups have been shown to have superior survivorship compared to implants made from any other material five years after surgery.

3 Dec 2010

Malvern Zetasizer Nano used to characterize environmentally responsive nanoparticles

The rapid, real-time measurement capabilities of the Zetasizer Nano system from Malvern Panalytical have enabled quantified nanoscale characterization of the environmental sensitivity of novel solubilization nanoparticles.

From Malvern Panalytical 28 Oct 2010

Sandoz initiates voluntary recall of Methotrexate Injection

Sandoz Inc. announced today it has initiated a voluntary recall in the US of all 50mg/2mL and 250mg/10mL vials of Sandoz and Parenta brand Methotrexate Injection, USP product ("methotrexate") to the consumer/user level. Consistent with its commitment to quality and patient safety, Sandoz is initiating this voluntary recall of all 24 lots of the affected product following the finding of small glass flakes by Sandoz quality control in a limited number of vials in four lots.

28 Oct 2010

Gymnemic acid nanocrystals could help develop soluble drug compounds

Researchers in India have demonstrated that producing nanoscopic crystals of a pharmaceutical product can allow the medication to be absorbed by the gut even if the drug is not soluble in water.

7 Oct 2010

Stirling Products’ drug delivery technology interests big ‘pharma’

Healthcare group, Stirling Products Limited (ASX:STI) has advised that following the recent TeleMedCare e-health acquisition and the conditional addition of the recently announced pathology business (subject to due diligence completion and shareholder approval), the Company is now in process of its strategised business integration.

26 Sep 2010

Lilly's Evista method patents upheld through March of 2014

Eli Lilly and Company today announced that the U.S. Court of Appeals for the Federal Circuit has affirmed a prior ruling by the U.S. District Court for the Southern District of Indiana that the company's method-of-use patents for Evista® (raloxifene HCl tablets) are valid. These patents provide protection for Evista in the U.S. through March of 2014.

2 Sep 2010

Phase 1 CRLX101 clinical study paves way for promising innovations in cancer therapy: Cerulean Pharma

Cerulean Pharma Inc., a leader in designing and developing nanopharmaceuticals, today announced that results of a Phase 1 clinical study of CRLX101 (formerly IT-101), Cerulean's lead clinical development candidate, and pre-clinical data on Cerulean's development candidate, CRLX288, were presented at the American Chemical Society National Meeting & Exposition, ongoing in Boston, Massachusetts.

26 Aug 2010

Variations in quality of illegal Class B drug mephedrone could risk safety of users

Pharmaceutical scientists have discovered that the recently reclassified drug mephedrone varies in quality so much that users could be at risk of overdosing. Six samples were tested in the University of Sunderland's labs by Dr John Lough and his team, and although impurities levels were low, three samples revealed various particle size and crystalline form, which means that the drug is more likely to vary in its affect and safety on the user.

15 Jul 2010

Scientists report potential toxicity of nanoparticles in consumer products

Scientists are reporting that particle size affects the toxicity of zinc oxide, a material widely used in sunscreens. Particles smaller than 100 nanometers are slightly more toxic to colon cells than conventional zinc oxide. Solid zinc oxide was more toxic than equivalent amounts of soluble zinc, and direct particle to cell contact was required to cause cell death.

25 Jun 2010

Malvern publishes online chemical imaging bibliography

By combining conventional spectroscopy with sophisticated mapping and imaging technology in its SyNIRgi chemical imaging system and ISys chemical imaging software, Malvern Panalytical has greatly extended the application of vibrational spectroscopy.

From Malvern Panalytical 3 Jun 2010

Nanosponge delivery system more effective at reducing tumor growth than direct injection: Study

When loaded with an anticancer drug, a delivery system based on a novel material called nanosponge is three to five times more effective at reducing tumor growth than direct injection.

3 Jun 2010

MicroStockProfit.com releases investment report on Discovery Laboratories

MicroStockProfit.com announces an investment report featuring Discovery Laboratories Inc. The report includes financial, comparative and investment analyses, and industry information you need to know to make an educated investment decision.

20 May 2010

Forest, Almirall to present data on aclidinium bromide for COPD and LAS100977 for asthma at ATS conference

Forest Laboratories, Inc. and Almirall, S.A. today announced that they are presenting data from several studies of two investigational inhaled respiratory compounds at the annual American Thoracic Society International Conference taking place in New Orleans May 14-19, 2010. Data on aclidinium bromide, an inhaled muscarinic antagonist, which is in Phase III development for COPD, and LAS100977, a long-acting beta 2-agonist, in Phase II development for asthma, will be presented in 11 separate posters.

11 May 2010

Enzyme technology developed to improve quality, safety and nutritional attributes of oat based foods

Oats is a highly nutritious cereal, which can be tolerated by large number of celiac patients. A range of commercial oat flours as well as specific oat flours produced from single varieties have been evaluated for their suitability for bread-baking. Enzyme technology, bioprocessing as well as high-pressure processing technology have been successfully applied to improve the quality, safety and nutritional attributes of oat based foods.

5 May 2010

Potential toxicity of zinc nanoparticles in sunscreen products

8 Apr 2010